(New York, USA) DelveInsight’s “Graft versus host disease Pipeline Insight – 2023” report provides comprehensive global coverage of available, marketed, and pipeline GVHD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Graft versus host disease pipeline domain.

 

Request for sample report @ Graft versus host disease Pipeline Report

 

Key Takeaways from the Graft versus host disease Pipeline Report

• DelveInsight’s Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Graft versus host disease treatment.
• Key Graft versus host disease companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for GVHD to improve the treatment landscape.
• Promising Graft versus host disease pipeline therapies in various stages of development include ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.

 

Request a sample and discover the recent advances in GVHD treatment drugs @ Graft versus host disease Pipeline Report

 

The Graft versus host disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Graft versus host disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the GVHD clinical trial landscape.

 

Graft versus host disease Overview

Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT).

 

Find out more about Graft versus host disease treatment drugs @ Drugs for Graft versus host disease Treatment

 

Graft versus host disease Pipeline Drugs mentioned in the report:

GvHD Drugs	Company	Phase	MoA	RoA
Itolizumab	Biocon	Phase III	CD6 antigen inhibitors	Intravenous
T-Guard	Xenikos	Phase III	T lymphocyte inhibitors; Protein synthesis inhibitors	Intravenous
MaaT013	MaaT Pharma	Phase III	Bacteria replacements; Gastrointestinal microbiome modulators	Rectal
Axatilimab	Syndax Pharmaceuticals	Phase II	Macrophage colony stimulating factor receptor antagonists	Intravenous
TQ 05105	Chia Tai Tianqing Pharmaceutical Group	Phase I/II	Janus kinase-2 inhibitors	Oral

 

Learn more about the emerging Graft versus host disease pipeline therapies @ Graft versus host disease Clinical Trials

 

Graft versus host disease Therapeutics Assessment

The Graft versus host disease pipeline report proffers an integral view of GVHD emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Graft versus host disease Pipeline Report 

• Coverage: Global 
• GVHD Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• GVHD Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Graft versus host disease Therapeutics Assessment By Route of Administration: Intravenous, Oral, Rectal.
• Key GVHD Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others

• Key GVHD Pipeline Therapies: ASC930, Teplizumab, MaaT013, Itolizumab, T-Guard, Axatilimab, TQ 05105, and others.

 

Dive deep into rich insights for new drugs for GVHD treatment; visit @ Graft versus host disease Medications

 

Table of Contents

Introduction

Executive Summary

Graft versus host disease (GVHD): Overview

What is Graft versus host disease (GVHD)?

Types of Graft versus host disease (GVHD)

Causes

Epidemiology and Risk Factors

Disease Management

GVHD Pipeline Therapeutics

Comparative Analysis

Graft versus host disease Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Graft versus host disease (GVHD)– DelveInsight’s Analytical Perspective

Late Stage Products (Preregistration)

Comparative Analysis

Itolizumab: Biocon

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

Comparative Analysis

ASC930: ASC Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

TQ 05105: Chia Tai Tianqing Pharmaceutical Group

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

Comparative Analysis

Graft versus host disease (GVHD) Key Companies

Graft versus host disease (GVHD) Key Products

Graft versus host disease (GVHD) Unmet Needs

Graft versus host disease (GVHD) Market Drivers and Barriers

Graft versus host disease (GVHD) Future Perspectives and Conclusion

Graft versus host disease (GVHD) Analyst Views

Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services